Chonluten dosage and protocol
Chonluten is a peptide bioregulator that has been studied for respiratory system and lung health support. It is part of the Khavinson peptide bioregulator family.
- Vial size: 20 mg
- Reconstitution: 3 mL bacteriostatic water
- Concentration: 6.67 mg/mL
- Administration: subcutaneous
Research areas
- Respiratory Health
- Lung Research
- Organ Protection
Quick start
- Reconstitute: Add 3 mL bacteriostatic water to the 20 mg vial for about 6.67 mg/mL
- Typical dose: 250 mcg once daily at the start, titrated every two weeks up to 4,000 mcg
- Easy measuring: At 6.67 mg/mL, 1 unit (0.01 mL) is about 67 mcg on a U-100 syringe, so 250 mcg is about 3.75 units and 1,000 mcg is 15 units
- Storage: Freeze lyophilized powder long-term; refrigerate at 2–8°C after mixing and avoid freeze-thaw
Dosing protocol
| Phase | Dose | Frequency | Volume |
|---|---|---|---|
| Weeks 1–2 | 250mcg | Once daily | 3.75 units (0.0375mL) |
| Weeks 3–4 | 500mcg | Once daily | 7.5 units (0.075mL) |
| Weeks 5–6 | 1000mcg | Once daily | 15 units (0.15mL) |
| Weeks 7–8 | 1500mcg | Once daily | 22.5 units (0.225mL) |
| Weeks 9–10 | 2000mcg | Once daily | 30 units (0.30mL) |
| Weeks 11–12 | 3000mcg | Once daily | 45 units (0.45mL) |
| Weeks 13–16 | 4000mcg | Once daily | 60 units (0.60mL) |
How it works
Chonluten is a synthetic tripeptide (Glu-Asp-Gly) belonging to the short peptide bioregulator family developed by Vladimir Khavinson and colleagues in Russia. It was designed from peptide fractions of bronchial mucosa and is proposed to act on tissues of the respiratory tract. The working hypothesis behind this class is that very short peptides can enter cells, interact with DNA or chromatin regions near gene promoters, and modulate the expression of tissue-specific genes rather than acting on a classic cell-surface receptor. In cell-culture and rodent work from the originating research group, Chonluten has been reported to influence expression of genes involved in inflammation and antioxidant defense in bronchial epithelial cells, and to affect markers of oxidative stress and inflammatory signaling in models of lung injury. Some reports describe changes in proteins such as heat-shock and inflammatory mediators, interpreted as a protective or normalizing effect on airway tissue. The evidence base is thin and concentrated in a small number of laboratories, with few independent replications and no well-designed, placebo-controlled human trials published in major international journals. Commercial bioregulator products have traditionally been oral capsules at low milligram doses; injectable use at the escalating doses listed here is not established by published research. Claims about lung health should therefore be treated as preliminary.
Reconstitution steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe
- Inject slowly down the vial wall; avoid foaming
- Gently swirl/roll until dissolved (do not shake)
- Label and refrigerate at 2–8°C, protected from light
Storage
Lyophilized: refrigerate at 4°C short-term or freeze at −20°C long-term. After reconstitution, refrigerate at 2–8°C; avoid freeze-thaw cycles.
Important notes
- Research only.
- Respiratory bioregulator.
- 10-day protocols.
- Lung-specific peptide.
Supplies
- Chonluten vial (20mg)
- Bacteriostatic water
- Insulin syringes
- Alcohol swabs